Persistence of Denosumab Therapy among Patients with Osteoporosis
- Author:
Kazuyoshi KOBAYASHI
1
;
Kei ANDO
;
Masaaki MACHINO
;
Masayoshi MOROZUMI
;
Shunsuke KANBARA
;
Sadayuki ITO
;
Taro INOUE
;
Hidetoshi YAMAGUCHI
;
Naoki ISHIGURO
;
Shiro IMAGAMA
Author Information
- Publication Type:Clinical Study
- From:Asian Spine Journal 2020;14(4):453-458
- CountryRepublic of Korea
- Language:English
-
Abstract:
Results:The study included 101 patients (84 females) with a median follow-up period of 23.6±14.2 months. The persistence rate declined to 85.3%, 78.3%, 74.1%, 71.3%, and 69.3% at 12, 24, 36, 48, and 60 months, respectively. Age at the initiation of denosumab therapy differed significantly between non-persistent (n=31) and persistent (n=70) patients (81.3 vs. 72.8 years, p <0.01). Persistence was significantly lower in patients aged ≥80 years than in those aged <60 and 60–79 years (both p <0.01). The reasons for non-persistence of denosumab therapy were transfer to another hospital (n=13), interruption of outpatient visits (n=11), dental treatment (n=4), adverse events (n=2), and patient request (n=1).
Conclusions:Persistence was significantly lower in patients aged ≥80 years than in patients of other ages, and strategies promoting persistence are needed for these elderly patients.
